SINGAPORE, May 22 /PRNewswire-FirstCall/ -- Edwards Lifesciences Corporation (NYSE: EW), the world leader in the science of heart valves, today announced the opening of its new heart valve manufacturing facility in Changi North Crescent, Singapore. The state-of-the-art facility produces Edwards' world-leading Carpentier-Edwards PERIMOUNT tissue heart valve replacements, and also serves as the headquarters for Edwards' Asia-Pacific operations, one of the company's fastest-growing regions.
"Edwards' new Singapore facility was developed to meet the global demands for our technologically advanced tissue heart valve replacement products," said Donald E. Bobo, Jr., Edwards' corporate vice president, heart valve therapy. "The opening coincides with our 50th anniversary of partnering with clinicians to develop life-saving innovations and we look forward to serving more patients around the world through our heart valve operations in the United States, Switzerland, and now, Singapore."
About Edwards Lifesciences
Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Headquartered in Irvine, Calif., Edwards treats advanced cardiovascular disease with its market-leading heart valve therapies, and critical care and vascular technologies. In 2008, Edwards celebrates 50 years of partnering with clinicians to develop life-saving innovations. The company's global brands, which are sold in approximately 100 countries, include CardioVations, Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, PERIMOUNT Magna and Swan-Ganz. Additional company information can be found at http://www.edwards.com
Edwards is a trademark of Edwards Lifesci
|SOURCE Edwards Lifesciences Corporation|
Copyright©2008 PR Newswire.
All rights reserved